Real-world comparative effectiveness of biologic therapies in severe asthma: EU-ADVANTAGE
The findings suggest that dupilumab may reduce severe exacerbations and OCS use in patients with SA better than omalizumab, benralizumab and mepolizumab in European real-world settings.
Authors
- J. Christian Virchow (ORCID: https://orcid.org/0000-0003-4291-1956)
- Lynn Huynh (ORCID: https://orcid.org/0000-0003-3110-6775)
- Giorgio Walter Canonica (ORCID: https://orcid.org/0000-0001-8467-2557)
- Juby A. Jacob‐Nara (ORCID: https://orcid.org/0000-0002-5372-8762)
- ARNAUD AB BOURDIN (ORCID: https://orcid.org/0000-0002-4645-5209)
- Richard H. Stanford (ORCID: https://orcid.org/0000-0001-5795-1147)
- Kinga Borsos
- Mena Soliman (ORCID: https://orcid.org/0000-0003-4066-1535)
- Mei Sheng Duh (ORCID: https://orcid.org/0000-0001-5035-6687)
- Fariha Haque
- Zhixiao Wang (ORCID: https://orcid.org/0000-0003-1928-3103)
- Wei‐Han Cheng
Institutions
- Centre National de la Recherche Scientifique (FR)
- Humanitas University (IT)
- Inserm (FR)
- Regeneron (United States) (US)
- Université de Montpellier (FR)
- AVEO Oncology (United States) (US)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Sanofi (United States) (US)
- Telesage (United States) (US)
- Universitätsmedizin Rostock (DE)
- Phelps Hospital (US)
- IRCCS Humanitas Research Hospital (IT)
- Analysis Group (United States) (US)
Publication Details
- Journal
- ERJ Open Research
- Published
- 2025-03-13
- DOI
- https://doi.org/10.1183/23120541.01217-2024
- Citations
- 2
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.33
Funders
- Sanofi
- Regeneron Pharmaceuticals